Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Why the study?
Does adjuvant trastuzumab improve disease-free survival with acceptable cardiac safety in breast cancer patients?
Population
Breast cancer patients who fulfill the HERA trial eligibility criteria
Design
RCT
Authors
Discussion
Loading...
Member takes
Implication
May support adjuvant decisions in breast cancer; leaves open randomized confirmation of cardiac safety and reversibility.
Structured PICO
Does adjuvant trastuzumab improve disease-free survival with acceptable cardiac safety in breast cancer patients?
P
Population
Breast cancer patients who fulfill the HERA trial eligibility criteria
I
Intervention
Adjuvant trastuzumab
O
Outcome
Disease-free survival and cardiac adverse eventssafety
Adjuvant trastuzumab is recommended for eligible breast cancer patients due to its disease-free survival benefit and low, potentially reversible risk of cardiac dysfunction.
Cite This Study
Suter et al. (2007) studied this question.